Genomics

A forgotten corner of oncology is set for a 14.2% CAGR. A new wave of drugs for chemo-induced neuropathy signals a major market realignment.

Nomic and the Wellcome Sanger Institute unite to profile immune diversity in underrepresented populations, using proteomics to bridge the gap from gene to function.

The PD-L1 biomarker testing market is set to double by 2036, fueling a revolution in cancer care. But as innovation races ahead, who gets left behind?

Komodo Health restructures its C-suite, signaling a major shift in healthcare. It's no longer about AI hype; it's about enterprise-scale dominance.

A record $1.15M campaign for blood cancer reveals a new playbook where executive influence, not just corporate checks, drives profound social impact.

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?

In a strategic pivot, GeneDx brings in former Quest and Thermo Fisher exec Mark Gardner to translate its genomic leadership into commercial dominance.

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

A new pact between Canada’s CASTL and Ireland’s NIBRT, backed by top leaders, aims to solve a critical talent shortage and secure the global pharma supply chain.

Verge Labs' new AI model promises to predict brain activity from a blood draw, potentially upending the costly and failure-prone world of neurology R&D.

Bruce Eaton's appointment as Chairman at Broken String isn't just a new hire; it's a strategic move to make its INDUCE-seq technology the industry's gold standard.

A 125-year-old pest control giant is funding a new generation of scientists, betting that the secrets of insects can solve our biggest future challenges.

Preliminary data from a randomized trial suggests a personalized medicine approach can reverse cognitive decline, offering a glimmer of hope beyond slowing the disease.

Activist investor Murchinson slams Nano Dimension’s pivot from 3D printing to epigenetics as a 'deeply flawed' deal, citing a 15% stock drop and echoes of past failures.

The FDA's approval of a new Type 1 Diabetes therapy is a landmark. But the real story is the collaborative engine clearing the path for future breakthroughs.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

With a $50M seed round, Radical Numerics aims to build general biological intelligence, walking a fine line between curing disease and creating bioweapons.

Legend Biotech's stunning trial results for an 'in vivo' CAR-T therapy could make advanced cancer treatment faster, safer, and accessible to all.

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

For 20 years, Montreal's Segal Cancer Centre has quietly built a world-class innovation engine. We dissect its unique model where research, care, and funding converge.